Roche’s cancer and inflammatory diseases drug, MabThera (rituximab), finally faces biosimilar competition in Europe, four years after its patent expired. The Swiss pharma has enjoyed several ...

Barcelona, Spain. New data presented at the EULAR meeting (European League Against Rheumatism) demonstrate that MabThera's (rituximab) effectiveness in relieving patients of the distressing ...

Washington, U.S. -- Data presented at this year's American College of Rheumatology Congress (ACR) show that patients receiving repeat treatment with MabThera/Rituxan (rituximab) achieved continued ...

The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016. However ...

MabThera shown to be effective and well tolerated over the long-term A study has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in ...

Roche Holding AG said on Wednesday that cancer drug MabThera, its biggest-selling product, also helps alleviate symptoms related to rheumatoid arthritis, a finding that significantly boosts the ...

Following Herceptin earlier this year, Roche has announced that tampered vials of it's blood cancer drug MabThera (Rituxan) were found in Germany. Swiss drugmaker Roche said on Friday that ...

NEW YORK Roche will present results of a study of its arthritis medication MabThera at a four-day meeting of the European League Against Rheumatism in Paris that begins Wednesday. The company ...

New hope for patients with most common form of leukaemia in adults Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved MabThera (rituximab) for use in ...

Medindia neither buys nor sells drugs. Rituximab (Mabthera) is a monoclol antibody, prescribed for certain types of cancer such as lymphomas, leukemia, transplant rejection and some autoimmune ...

Basel, 15 March 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe ...

ZURICH (Reuters) - Roche Holding AG said on Friday its top-selling cancer drug MabThera helped patients with Chronic Lymphocytic Leukaemia (CLL) to live longer without their disease getting worse ...